Progression-Free Survival (PFS) [clinicaltrials_resource:NCT00977561/outcome/1]
outcome [clinicaltrials_vocabulary:outcome]
Progression-Free Survival (PFS) [clinicaltrials_resource:NCT00977561/outcome/1]
Bio2RDF identifier
NCT00977561/outcome/1
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:NCT00977561/outcome/1
group [clinicaltrials_vocabulary:group]
measure [clinicaltrials_vocabulary:measure]
population [clinicaltrials_vocabulary:population]
All randomized participants wh ...... cluded in the safety analysis.
No analysis for NRS score was ...... or carboplatin) and etoposide.
No analysis for cancer dyspnea ...... or carboplatin) and etoposide.
No analysis for serum circulat ...... or carboplatin) and etoposide.
No analysis of ADA response wa ...... or carboplatin) and etoposide.
No analysis of Cmax for figitu ...... or carboplatin) and etoposide.
No analysis of Cmin for figitu ...... or carboplatin) and etoposide.
No analysis of PK parameters f ...... or carboplatin) and etoposide.
No analysis of objective respo ...... or carboplatin) and etoposide.
No analysis of overall surviva ...... or carboplatin) and etoposide.
safety issue [clinicaltrials_vocabulary:safety-issue]
time frame [clinicaltrials_vocabulary:time-frame]
Baseline (Cycle 1, Day 1 prior ...... ys post last figitumumab dose)
Baseline (Cycle 1, Day 1), Cyc ...... ys post last figitumumab dose)
Baseline prior to dosing
Baseline up to follow-up (90 days post dose)
Baseline, every 2nd cycle (bet ...... eeks until disease progression
Cycle 1, Day 2; Day 1 of Cycle ...... 90 post last figitumumab dose
Cycles 1 and 2, Day 1 and Day ...... post Day 1 etoposide infusion
Day 1 of every cycle (up to 17 ...... eeks until disease progression
Day 2 of Cycle 1 (or Day 1 of ...... 90 post last figitumumab dose
Every 3 months until death or 12 months from the date the last participant was randomized
type [clinicaltrials_vocabulary:type]
alternate
Progression-Free Survival (PFS)
@en
identifier
clinicaltrials_resource:NCT00977561/outcome/1
title
Median time from the first dos ...... - date of randomization + 1].
@en
type
label
Progression-Free Survival (PFS) [clinicaltrials_resource:NCT00977561/outcome/1]
@en